PromoCell launches custom GMP cell culture media to power next-gen cell and gene therapies

New offering to debut at the 32nd ESGCT Congress, October 7–10, 2025, in Seville, Spain

Enhertu approved in US for breast cancer post more endocrine therapies

Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year

AbbVie and Gilgamesh Pharmaceuticals collaborate to develop next-gen therapies for psychiatric disorders

Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders

Bristol Myers Squibb and Cellares inks US$ 380 million capacity reservation for the manufacture of CAR T Cell Therapies

Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use

Celanese and Secarna Pharmaceuticals collaborate for RNA research for antisense therapies

Reclassify nicotine replacement therapies as prescription drugs, says Doctor

NRT offers 50% higher success rate in quitting smoking compared to unassisted attempts

Sartorius Bioreactors integrate Emerson Technology to speed new therapies to market

DeltaV control system natively integrated into Sartorius Biostat STR bioreactors provide a foundation for semi-autonomous operations and up to 80% less integration time

Novartis acquires DTx Pharma to develop siRNA therapies

Deal includes DTx-1252, a potential therapy for the neuromuscular disorder Charcot-Marie-Tooth disease type 1A (CMT1A), and two additional preclinical programs for other neuroscience indications

NMPA approval for first BCMA CAR-T Therapy paves way for more multiple myeloma cell therapies, says GlobalData

Approval to dramatically change CAR-T therapies landscape

LyGenesis and Imagine Pharma to jointly develop cell therapies for Patients with Type 1 diabetes

Collaboration will enable rapid advancement of a joint preclinical proof of concept program for type 1 diabetes